The Duke Clinical & Translational Science Institute has been awarded a five-year grant of more than $60 million from the National Institutes of Health (NIH) to advance innovative ideas from the point of discovery to implementation in clinical practice and population health.
The Clinical and Translational Science Awards (CTSA) program, supported by the NIH’s National Center for Advancing Translational Sciences, provides infrastructure for researchers at Duke to conduct clinical research, train young scientists and share developments across a consortium of more than 60 other leading centers throughout the world.
Duke received one of the original 12 CTSA grants in 2006, with a previous renewal of $47 million in 2013.
“With the NIH’s support, Duke CTSA will continue to lead in translating research discoveries into health benefits,” said A. Eugene Washington, M.D., Duke University chancellor for health affairs and president and CEO of Duke University Health System. “And we are gratified that the many distinguished achievements and significant contributions of our faculty, staff and trainees are recognized through this renewed investment.”
Three principal investigators lead Duke’s CTSA program, including L. Ebony Boulware, M.D., chief of the Division of General Internal Medicine, vice dean for translational science, and associate vice chancellor for translational research in the School of Medicine; Jennifer Li, M.D., chief of the Division of Pediatric Cardiology; and James McNamara, M.D., director of the Center for Translational Neuroscience.
“Renewal of the CTSA is an important validation of the immense efforts of so many individuals across our campus. I am so appreciative of the innovative and hard work that the CTSA team lead by Dr. Boulware, put into this successful renewal,” said Mary E. Klotman, M.D., dean of the Duke University School of Medicine. “With this support, significant efforts to train and support our researchers and staff, increase engagement with our community and accelerate scientific discovery into improved care for patients can continue in earnest.”